E
Calliditas Therapeutics AB (publ) CALT
NASDAQ
Recommendation
Sell
Prev Close
$40.00
Volume
--
Avg Vol (90D)
13,409
Market Cap
$1.09B
Dividend & Yield
--
52-Week Range
$15.25 - $43.00
P/E (TTM)
--
EPS (TTM)
-$0.8464
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Good
Volatility Index
Weak
Dividend Index
--
Headlines
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Reaches New 1-Year High at $43.00
9/22/2024 - Zolmax
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Reaches New 52-Week High at $43.00
9/20/2024 - Ticker Report
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
9/16/2024 - PR Newswire
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
9/9/2024 - Zacks Investment Research
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
9/3/2024 - PR Newswire
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
9/3/2024 - PR Newswire
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Unusually-High Trading Volume
8/29/2024 - Ticker Report
Head-To-Head Analysis: Calliditas Therapeutics AB (publ) (NASDAQ:CALT) versus Dyne Therapeutics (NASDAQ:DYN)
8/28/2024 - Ticker Report
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives $35.00 Consensus Price Target from Analysts
8/17/2024 - Ticker Report
Calliditas Therapeutics AB (CALT) Q2 2024 Earnings Call Transcript Highlights: Record Revenues ...
8/15/2024 - GuruFocus
Q2 2024 Calliditas Therapeutics AB Earnings Call Transcript
8/15/2024 - GuruFocus
Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript
8/13/2024 - SeekingAlpha
Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript
8/13/2024 - Seeking Alpha: Transcripts
CALT Stock Earnings: Calliditas Therapeutics Misses EPS, Beats Revenue for Q2 2024
8/13/2024 - InvestorPlace
Calliditas Interim Report January to June 2024
8/13/2024 - PR Newswire
Invitation to the presentation of Calliditass interim report January - June 2024
8/5/2024 - PR Newswire
Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference
8/1/2024 - Globe Newswire
Number of shares and votes in Calliditas Therapeutics
7/31/2024 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DRQ, LSAK, CALT on Behalf of Shareholders
7/29/2024 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BALY, MRO, SHCR, CALT on Behalf of Shareholders
7/27/2024 - Globe Newswire
STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB CALT
7/27/2024 - Globe Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders
7/26/2024 - PR Newswire
STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT
7/26/2024 - PR Newswire
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo for the treatment of IgA Nephropathy
7/26/2024 - PR Newswire
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
7/26/2024 - PR Newswire
Income Statement
Total Revenue (TTM)
$150.52M
EBITDA (TTM)
-$34.70M
EBIT (TTM)
-$35.04M
Net Income (TTM)
-$45.43M
Balance Sheet
Total Assets (Q)
$164.85M
Total Debt (Q)
$95.13M
Total Liabilities (Q)
$154.77M
Book Value Per Share (Q)
$0.1865
Cash Flow
Cash from Operations (TTM)
-$23.37M
Cash from Investing (TTM)
-$1.29M
Cash from Financing (TTM)
$18.44M
Net Change in Cash (TTM)
-$6.71M
Filings
Filing Date
Tuesday, August 13, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Week of Nov 4 and 8 (est)
Price History
Loading...
Beta
0.40
7-Day Total Return
--
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
--
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Nov 13, 2023 - $15.25
52-week High
Sep 20, 2024 - $43.00
Valuation
Market Cap
$1.09B - Small Cap
Enterprise Value
$1.11B
Price/Sales (TTM)
14.27
Price/Book (Q)
214.48
Dividends and Shares
Shares Outstanding
53.69M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.calliditas.se
Phone Number
46 84 11 30 05
Address
Kungsbron 1, D5
Stockholm, 111 22
Country
Sweden
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial... more
Weiss Ratings